Inhibikase Therapeutics, Inc. - Common Stock (IKT)
Seasonality Analysis
Inhibikase Therapeutics, Inc. - Common Stock Annual Seasonality Statistics
Inhibikase Therapeutics, Inc. - Common Stock Monthly Seasonality Performance
| Month | Avg Return | Win Rate | Strength |
|---|---|---|---|
| January BEST | 13.86% | Weak | |
| February | -2.42% | Weak | |
| March | 0.37% | Weak | |
| April | -12.59% | Very Weak | |
| May | 7.73% | Moderate | |
| June WORST | -26.87% | Very Weak | |
| July | -8.37% | Weak | |
| August | 3.38% | Very Strong | |
| September | -13.13% | Very Weak | |
| October | 10.23% | Weak | |
| November | -1.40% | Weak | |
| December | 4.06% | Weak |
Inhibikase Therapeutics, Inc. - Common Stock 2026 vs Historical Pattern
Inhibikase Therapeutics, Inc. - Common Stock Interactive Seasonality Chart
Inhibikase Therapeutics, Inc. - Common Stock Pattern Scanner
Inhibikase Therapeutics, Inc. - Common Stock Seasonal Historical Performance
About Inhibikase Therapeutics, Inc. - Common Stock (IKT) Seasonality
Inhibikase Therapeutics, Inc. - Common Stock (IKT) has been analyzed using 6 years of historical data to identify seasonal patterns. Classified under Stocks, Inhibikase Therapeutics, Inc. - Common Stock shows distinct seasonal tendencies based on historical data.
The strongest month for Inhibikase Therapeutics, Inc. - Common Stock is historically January, with an average return of 13.86% and a win rate of 33%. Conversely, June tends to be the weakest month, averaging -26.87% return.
Looking at the full calendar year, Inhibikase Therapeutics, Inc. - Common Stock has an average annual return of -25.16% with an overall monthly win rate of 38.6%. Out of 12 months, 6 typically show positive average returns.
The seasonal pattern for Inhibikase Therapeutics, Inc. - Common Stock has a consistency score of 69.3 (Good), based on 7 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.
Inhibikase Therapeutics, Inc. - Common Stock Seasonality FAQ
What is the best month to buy Inhibikase Therapeutics, Inc. - Common Stock (IKT)?
Historically, January has been the best month for Inhibikase Therapeutics, Inc. - Common Stock, with an average return of 13.86% and a win rate of 33%. However, past performance does not guarantee future results.
What is the worst month for Inhibikase Therapeutics, Inc. - Common Stock (IKT)?
Based on historical data, June has been the weakest month for Inhibikase Therapeutics, Inc. - Common Stock, with an average return of -26.87%. This is a historical observation and does not guarantee future results.
How reliable is IKT seasonality data?
The seasonality analysis for Inhibikase Therapeutics, Inc. - Common Stock is based on 6 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.
How can I use Inhibikase Therapeutics, Inc. - Common Stock seasonality in my trading?
Use Inhibikase Therapeutics, Inc. - Common Stock (IKT) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.